Journal of Clinical Oncology, Vol 16, 3316-3322, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

H Choy, W Akerley, H Safran, S Graziano, C Chung, T Williams, B Cole and T Kennedy
Vanderbilt University Medical School, Nashville, TN, USA. hak.choy@mcmail.vanderbilt.edu

PURPOSE: Combined modality therapy for non-small-cell lung cancer (NSCLC) has produced promising results. A multiinstitutional phase II clinical trial was conducted to evaluate the activity and toxicity of paclitaxel, carboplatin, and concurrent radiation therapy on patients with locally advanced NSCLC. PATIENTS AND METHODS: Forty previously untreated patients with inoperable locally advanced NSCLC entered onto a phase II study from March 1995 to December 1996. On an outpatient basis for 7 weeks, patients received paclitaxel 50 mg/m2 weekly over 1 hour; carboplatin at (area under the curve) AUC 2 weekly; and radiation therapy of 66 Gy in 33 fractions. After chemoradiation therapy, patients received an additional two cycles of paclitaxel 200 mg/m2 over 3 hours and carboplatin at AUC 6 every 3 weeks. RESULTS: Thirty-nine patients were eligible for the study. The survival rates at 12 months were 56.3%, and at 24 months, 38.3%, with a median overall survival of 20.5 months. The progression-free survival rates at 12 months were 43.6%, and at 24 months, 34.7%, with a median progression-free survival of 9.0 months. Two patients did not receive more than 2 weeks of concurrent chemoradiotherapy and were not assessable for toxicity and response. The overall response rate (partial plus complete response) of 37 assessable patients was 75.7%. The major toxicity was esophagitis. Seventeen patients (46%) developed grade 3 or 4 esophagitis. However, only two patients developed late esophageal toxicity with stricture at 3 and 6 months posttreatment. CONCLUSION: Combined modality therapy with paclitaxel, carboplatin, and radiation is a promising treatment for locally advanced NSCLC that has a high response rate and acceptable toxicity and survival rates. A randomized trial will be necessary to fully evaluate the usefulness of these findings.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Mutter, B. Lu, D. P. Carbone, I. Csiki, L. Moretti, D. H. Johnson, J. D. Morrow, A. B. Sandler, Y. Shyr, F. Ye, et al. A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer Clin. Cancer Res., March 15, 2009; 15(6): 2158 - 2165. [Abstract] [Full Text] [PDF]

				K. Kelly, K. Chansky, L. E. Gaspar, K. S. Albain, J. Jett, Y. C. Ung, D. H.M. Lau, J. J. Crowley, and D. R. Gandara Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023 J. Clin. Oncol., May 20, 2008; 26(15): 2450 - 2456. [Abstract] [Full Text] [PDF]

				E. E. Vokes, J. E. Herndon II, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. Neill, J. N. Atkins, D. M. Watson, W. Akerley, and M. R. Green Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B J. Clin. Oncol., May 1, 2007; 25(13): 1698 - 1704. [Abstract] [Full Text] [PDF]

				I. Sekine, M. Sumi, Y. Ito, T. Kato, Y. Fujisaka, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., April 23, 2007; (2007) hym008v1. [Abstract] [Full Text] [PDF]

				S. G. Divers, S. A. Spencer, D. Carey, E. M. Busby, M. D. Hyatt, and F. Robert Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6664 - 6673. [Abstract] [Full Text] [PDF]

				E. E. Vokes Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5853 - 5855. [Full Text] [PDF]

				C. P. Belani, H. Choy, P. Bonomi, C. Scott, P. Travis, J. Haluschak, and W. J. Curran Jr Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol J. Clin. Oncol., September 1, 2005; 23(25): 5883 - 5891. [Abstract] [Full Text] [PDF]

				E. E. Vokes, J. Crawford, J. Bogart, M. A. Socinski, G. Clamon, and M. R. Green Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5045s - 5050s. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., February 20, 2005; 23(6): 1144 - 1151. [Abstract] [Full Text] [PDF]

				Y. Hasegawa, S. Takanashi, K. Okudera, M. Aoki, K. Basaki, H. Kondo, T. Takahata, N. Yasui-Furukori, T. Tateishi, Y. Abe, et al. Weekly Paclitaxel and Nedaplatin With Concurrent Radiotherapy for Locally Advanced Non-small-cell Lung Cancer: a Phase I/II Study Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 647 - 653. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				D. R. Gandara, K. Chansky, K. S. Albain, B. R. Leigh, L. E. Gaspar, P. N. Lara Jr, H. Burris, P. Gumerlock, J. P. Kuebler, J. D. Bearden III, et al. Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non-Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 J. Clin. Oncol., May 15, 2003; 21(10): 2004 - 2010. [Abstract] [Full Text] [PDF]

				S. S. Leong, E. H. Tan, K. W. Fong, E. Wilder-Smith, Y. K. Ong, B. C. Tai, L. Chew, S. H. Lim, J. Wee, K. M. Lee, et al. Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1767 - 1774. [Abstract] [Full Text] [PDF]

				L. J. Wirth, J. Lucca, P. Ostler, P. Fidias, C. Lynch, P. A. Janne, R. S. Herbst, B. E. Johnson, D. J. Sugarbaker, D. J. Mathisen, et al. Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: A Phase I Study Clin. Cancer Res., May 1, 2003; 9(5): 1698 - 1704. [Abstract] [Full Text] [PDF]

				K. S. Albain, J. J. Crowley, A. T. Turrisi III, D. R. Gandara, W. B. Farrar, J. I. Clark, K. R. Beasley, and R. B. Livingston Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 J. Clin. Oncol., August 15, 2002; 20(16): 3454 - 3460. [Abstract] [Full Text] [PDF]

				D. Lau, B. Leigh, D. Gandara, M. Edelman, R. Morgan, V. Israel, P. Lara, R. Wilder, J. Ryu, and J. Doroshow Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non-Small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial J. Clin. Oncol., January 15, 2001; 19(2): 442 - 447. [Abstract] [Full Text] [PDF]

				M. Ando, H. Minami, Y. Ando, H. Saka, S. Sakai, M. Yamamoto, Y. Sasaki, K. Shimokata, and Y. Hasegawa Multi-Institutional Validation Study of Carboplatin Dosing Formula Using Adjusted Serum Creatinine Level Clin. Cancer Res., December 1, 2000; 6(12): 4733 - 4738. [Abstract] [Full Text]